MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 08-06-2025
iTeos Therapeutics EPS Ratio 2011-2026 | ITOS
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio iTeos Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -3.32 | -3.15 | 2.72 | 6.1 | -2.88 | -131 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6.1 | -131 | -21.9 |
Quarterly EPS Ratio iTeos Therapeutics
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.81 | -0.8 | - | -1.05 | -0.18 | -1.07 | - | -0.9 | -0.96 | -0.44 | - | 0.03 | 0.16 | 1.96 | - | 1.98 | -0.75 | -0.39 | - | -0.48 | -29.5 | -25.5 | - | -43 | -36.5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.98 | -43 | -7.33 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Biotechnology industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
ACADIA Pharmaceuticals
ACAD
|
1.37 | $ 22.57 | 0.04 % | $ 3.74 B |  USA |
 |
MorphoSys AG
MOR
|
-15.4 | - | 2.43 % | $ 254 M |  Germany |
 |
Adverum Biotechnologies
ADVM
|
-6.62 | - | - | $ 86.2 M | USA |
 |
Acorda Therapeutics
ACOR
|
-204 | - | -24.86 % | $ 820 K | USA |
 |
Allakos
ALLK
|
-2.14 | - | - | $ 28.6 M | USA |
 |
Akebia Therapeutics
AKBA
|
-0.02 | $ 1.41 | -1.4 % | $ 363 M | USA |
 |
AlloVir
ALVR
|
-2.85 | - | 4.14 % | $ 49.1 M | USA |
 |
Applied Molecular Transport
AMTI
|
-3.25 | - | - | $ 10.1 M | USA |
 |
I-Mab
IMAB
|
-7.66 | - | - | $ 866 M |  China |
 |
Genfit SA
GNFT
|
1.51 | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-0.26 | - | -13.47 % | $ 169 M | France |
 |
Applied Therapeutics
APLT
|
-1.42 | - | - | $ 8.42 M | USA |
 |
Aravive
ARAV
|
-2.1 | - | -13.39 % | $ 1.45 M | USA |
 |
Midatech Pharma plc
MTP
|
-31 | - | -18.52 % | $ 27.3 M |  Britain |
 |
BioNTech SE
BNTX
|
42.2 | $ 91.98 | -0.11 % | $ 27.2 B | Germany |
 |
Aytu BioScience
AYTU
|
-2.16 | $ 2.56 | -3.76 % | $ 16.1 M | USA |
 |
AstraZeneca PLC
AZN
|
0.08 | - | - | $ 96.9 B | Britain |
 |
Alterity Therapeutics Limited
ATHE
|
-0.53 | $ 3.85 | -1.39 % | $ 9.26 B |  Australia |
 |
AVROBIO
AVRO
|
0.27 | - | 1083.1 % | $ 745 M | USA |
 |
Advaxis
ADXS
|
-7.99 | - | -9.65 % | $ 45.9 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
2.1 | $ 20.87 | 2.3 % | $ 976 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-1.11 | - | -2.5 % | $ 5.88 M | USA |
 |
Aquestive Therapeutics
AQST
|
-0.78 | $ 4.17 | -0.24 % | $ 446 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-2.46 | - | - | $ 7.46 M |  Israel |
 |
Arcutis Biotherapeutics
ARQT
|
-0.13 | $ 24.57 | -0.16 % | $ 3.13 B | USA |
 |
BeiGene, Ltd.
BGNE
|
0.2 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Aeterna Zentaris
AEZS
|
-0.07 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-1.91 | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-24.9 | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-0.36 | - | - | $ 26.5 M | USA |
 |
CymaBay Therapeutics
CBAY
|
-0.99 | - | - | $ 3.45 B | USA |
 |
AIkido Pharma
AIKI
|
-1.57 | - | 1.93 % | $ 17.4 M | USA |
 |
Cabaletta Bio
CABA
|
-2.1 | $ 3.17 | 2.59 % | $ 319 M | USA |
 |
Codiak BioSciences
CDAK
|
-1.7 | - | -55.98 % | $ 2.15 M | USA |
 |
Aptose Biosciences
APTO
|
-10.4 | - | -45.71 % | $ 1.2 M | Canada |
 |
Avid Bioservices
CDMO
|
-2.23 | - | - | $ 789 M | USA |
 |
Cidara Therapeutics
CDTX
|
-26.8 | - | - | $ 1.41 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-0.01 | $ 2.93 | -4.87 % | $ 6.38 B | Israel |
 |
Akero Therapeutics
AKRO
|
-3.75 | - | - | $ 3.67 B | USA |
 |
Checkpoint Therapeutics
CKPT
|
-1.42 | - | - | $ 169 M | USA |
 |
CureVac N.V.
CVAC
|
-2.21 | - | - | $ 867 M | Germany |
 |
Celldex Therapeutics
CLDX
|
-3.9 | $ 33.62 | 3.73 % | $ 2.23 B | USA |
 |
Concert Pharmaceuticals
CNCE
|
-2.33 | - | - | $ 401 M | USA |
 |
Akari Therapeutics, Plc
AKTX
|
-0.09 | $ 3.92 | 1.03 % | $ 264 B | Britain |
 |
Akouos
AKUS
|
-2.52 | - | 0.23 % | $ 488 M | USA |
 |
Celsion Corporation
CLSN
|
-6.83 | - | -6.63 % | $ 13.9 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-0.72 | - | 3.16 % | $ 1.9 M | USA |